Brian D. Kangas

NIH Rank #637
  • Top 5% by Linked Awards
  • R01 Award PI

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 9293028Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2025 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2026

Linked Award Amount
$4.1M
Full award amounts, FY2026
Award Records
2
Records listing this PI
Award-Linked Rank
#637
By linked amount among FY2026 PIs
Earliest Year Loaded
2025
ScienceDex PI coverage

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Brian D. Kangas as a PI. Multi-PI records show the full award amount for context.

  • 4RF1MH136052-02RF1
    MDMA Mechanisms of Prohedonic Efficacy: A Reverse Translational Approach
    $2.9M
    award amount
  • 5R01DA047575-07R01
    Neural and Behavioral Consequences of Chronic THC Exposure During Adolescence
    $1.2M
    award amount

Award organization

Organizations that administered FY2026 awards listing Brian D. Kangas as a PI.

FY2026 award administered by McLean Hospital (MA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2025
    ScienceDex Coverage Begins
    Earliest loaded PI award records: FY2025
  2. 2025
    $500K Cumulative Linked Award Amount
  3. 2025
    $1M Cumulative Linked Award Amount
  4. 2025
    Reached Top 50% by Award-Linked Rank
    Ranked #7040
  5. 2025
    R01 Award Record
  6. 2026
    $2M Cumulative Linked Award Amount
  7. 2026
    $5M Cumulative Linked Award Amount
  8. 2026
    Reached Top 25% by Award-Linked Rank
    Ranked #637
  9. 2026
    Reached Top 10% by Award-Linked Rank
    Ranked #637
  10. 2026
    Reached Top 5% by Award-Linked Rank
    Ranked #637

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Brian D. Kangas.